Robert LeBoyer, Senior Vice President, Equity Research Analyst, Biotechnology, Noble Capital Markets, Inc.
Refer to the full report for the price target, fundamental analysis, and rating.
3Q26 Reported With Start Of OCU410 Phase 2/3 Trial. Ocugen reported a loss of $3.6 million, or $(0.01) per share, including a non-cash gain of $16.6 million from Change In Fair Value of Derivatives. Without this gain, Net Loss would have been $20.2 million, or $(0.06) per share. This adjusted Net Loss is consistent with previous quarters and our estimates for 3Q26. Cash and equivalents were $84.6 million as of September 30, 2026, which we expect to fund operations through 2028.
OCU400 In Retinitis Pigmentosa. The Phase 3 liMeliGhT (pronounced Limelight) trial continues, with data expected to be announced in 1Q2027. The Process Performance Qualification (PPQ) batches for the CMC section of the BLA have been completed. As discussed in our Research Note on September 28, the Bahamas has granted Provisional Approval and Priority Designation for OCU400. We continue to expect submission of the BLA to the FDA and an MAA in Europe, with approval later in FY2027.
Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.
This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).
*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision.
Robert LeBoyer, Senior Vice President, Equity Research Analyst, Biotechnology, Noble Capital Markets, Inc.
Refer to the full report for the price target, fundamental analysis, and rating.
New Data Presentation On Quality of Life and Symptoms. Eledon presented data from the Phase 2 BESTOW trial at the American Society of Nephrology Annual Kidney Week 2026 meeting. The presentation compared patients receiving tegoprubart with those receiving tacrolimus, showing improvements in quality of life and reductions in symptom burden at 12 months. We believe these findings support prior data on efficacy, safety, and tolerability.
Patient Evaluations. Data from two accepted clinical evaluations, MTSOSD-59R and KDQOL-SF, showed substantial, lasting improvements in quality of life and reductions in transplant-related side effects. We see these patient-reported outcomes as consistent with prior reductions in BPAR (Biopsy-Proven Acute Rejection), improvements in eGFR, and improvements in factors that contribute to long-term graft failure.
Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.
This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).
*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision.
Tegoprubart-treated patients demonstrated a mean improvement on the total MTSOSD-59R symptom occurrence scale at 12 months while tacrolimus-treated patients experienced a mean worsening of symptom occurrence
Statistically significant improvement on the KDQOL-SF Symptoms and Problems Scale among tegoprubart-treated patients through 12 months following kidney transplantation versus tacrolimus
Results further validate the differentiated clinical profile of tegoprubart and potential to transform standard of care in kidney transplantation
IRVINE, Calif., Oct. 26, 2026 (GLOBE NEWSWIRE) — Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: ELDN) today announced new positive patient-reported outcomes data from the Phase 2 BESTOW clinical trial of tegoprubart, its novel investigational immunosuppression therapy. The data showed significant, sustained improvements in health-related quality of life and symptom burden through 12 months compared with standard of care tacrolimus following kidney transplantation. The results were featured in an oral presentation at the American Society of Nephrology (ASN) Kidney Week 2026 Annual Meeting held October 21-25, 2026, in Denver, Colorado.
“The patient-reported outcomes presented at ASN Kidney Week provide perhaps the clearest picture yet of what tegoprubart’s differentiated profile means for transplant patients in everyday life,” said David-Alexandre C. Gros, M.D., Chief Executive Officer of Eledon. “We previously reported encouraging BESTOW results across efficacy, kidney function and safety measures, which alone strengthened our belief in tegoprubart. The additional findings presented demonstrate that these clinical outcomes were accompanied by substantial and importantly sustained improvements in quality of life and reductions in transplant-related symptom burden. Giving transplant patients an effective, safer and more tolerable alternative to tacrolimus addresses one of the most important unmet needs in organ transplantation, and collectively, these data further support the potential of tegoprubart to become a transformative new treatment option for kidney transplant recipients.”
“Success after kidney transplantation is measured not only by preventing rejection and preserving graft function, but also by how patients feel and function in their everyday lives,” said presenting author Andrew Adams, M.D., Ph.D., Professor of Surgery and Chief, Division of Transplantation, John S. Najarian Surgical Chair in Clinical Transplantation, Department of Surgery, University of Minnesota. “What is particularly compelling about these BESTOW results is the consistency of the patient-reported benefits when treated with tegoprubart compared with tacrolimus following kidney transplant. We observed broad improvements in quality-of-life measures together with remarkably favorable outcomes in transplant-specific symptom reporting. The extent of separation between treatment groups suggests patients receiving tegoprubart may experience meaningful quality of life advantages while maintaining strong clinical outcomes as previously reported from BESTOW.”
Patient-Reported Outcomes Results
Patient-reported outcomes were assessed using the Modified Transplant Symptom Occurrence and Symptom Distress Scale (MTSOSD-59R) and the Kidney Disease Quality of Life Short Form (KDQOL-SF) Symptoms and Problems Scale, both validated measures of symptom burden. Baseline scores were similar between treatment groups. Collectively, the consistency of findings across both the KDQOL-SF and MTSOSD-59R assessments suggests that reductions in transplant-related symptom burden with tegoprubart may contribute to the improvements observed in patient-reported quality of life and further supports the differentiated clinical profile of tegoprubart compared to tacrolimus observed in the Phase 2 BESTOW clinical trial.
On the MTSOSD-59R assessment, tegoprubart-treated patients reported continued reductions in symptom occurrence from baseline at Months 6 and 12, whereas symptom occurrence in the tacrolimus arm initially declined through Month 6 before returning to slightly above baseline levels at Month 12.
CI, confidence interval; KDQOL-SF, Kidney Disease Quality of Life Short Form; MTSOSD-59R, Modified Transplant Symptom Occurrence Scale- 59 Items Revised; SEM, standard error of the mean; tac, tacrolimus; tego, tegoprubart.
Tegoprubart demonstrated greater symptom improvement than tacrolimus in 22 of 23 domains where differential improvement was observed, including neurological, gastrointestinal, metabolic, and physical symptom categories. In addition, tacrolimus demonstrated greater symptom worsening in 22 of 22 domains where differential symptom worsening was observed.
On the KDQOL-SF assessment, kidney transplant patients treated with tegoprubart demonstrated improvements from baseline across all five subscales through Month 12. In the KDQOL-SF scale, a change of 3-5 points can be considered clinically significant, and tegoprubart was thus associated with a clinically and statistically significant improvement in the symptoms and problems subscale compared with tacrolimus at Month 12, with mean changes from baseline of 9.0 and 3.3 points, respectively (p<0.05). Consistent with these findings, the SF-12 mental component summary score increased by 1.5 points in the tegoprubart arm compared to a decline of 1.6 points in the tacrolimus arm, representing a 3.1-point between-group difference.
a Higher scores indicate better HRQoL; a change of 3–5 points can be considered clinically significant1. Baseline values were similar across all outcomes. *p < 0.05. HRQoL, health-related quality of life; KDQOL-SF, Kidney Disease Quality of Life Short-Form instrument; SEM, standard error of the mean; SF-12, 12-item short-form survey; tac, tacrolimus; tego, tegoprubart.1. KDOQI. Am J Kidney Dis 2007;50:471–530.
Details of the oral presentation at ASN Kidney Week 2026 are below:
Title: Patient-Reported Outcomes in the Phase 2 BESTOW Trial Comparing Tegoprubart to Tacrolimus in Kidney Transplant Recipients Presenter: Andrew B. Adams, M.D., Ph.D., Department of Surgery, University of Minnesota Medical School; Minneapolis, Minnesota Abstract Publication Number: FR-OR084 Session Title: The Changing Landscape of Kidney Transplantation: Clinical Innovation, Outcomes, and Healthy Policy Session Date and Time: Friday, October 23, 2026, from 4:30 p.m. to 6:00 p.m. MDT Session Room: Mile High Ballroom 4A (Convention Center) Presentation Time: 4:40 p.m. to 4:50 p.m. MDT
About Eledon Pharmaceuticals and tegoprubart
Eledon Pharmaceuticals, Inc. is a clinical stage biotechnology company that is developing immune-modulating therapies for the management and treatment of life-threatening conditions. The Company’s lead investigational product is tegoprubart, an anti-CD40L antibody with high affinity for the CD40 Ligand, a well-validated biological target that has broad therapeutic potential. The central role of CD40L signaling in both adaptive and innate immune cell activation and function positions it as an attractive target for non-lymphocyte depleting, immunomodulatory therapeutic intervention. The Company is building upon a deep historical knowledge of anti-CD40L biology to conduct preclinical and clinical studies in kidney allograft transplantation, xenotransplantation, islet cell transplantation, liver transplantation and amyotrophic lateral sclerosis (ALS). Eledon is headquartered in Irvine, California. For more information, please visit the Company’s website at www.eledon.com.
Follow Eledon Pharmaceuticals on social media: LinkedIn; X
Forward-Looking Statements
This press release contains forward-looking statements that involve substantial risks and uncertainties. Any statements about the company’s future expectations, plans and prospects, including statements about planned clinical trials, the development of product candidates, expected timing for initiation of future clinical trials, expected timing for receipt of data from clinical trials, as well as other statements containing the words “believes,” “anticipates,” “plans,” “expects,” “estimates,” “intends,” “predicts,” “projects,” “targets,” “looks forward,” “could,” “may,” and similar expressions, constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Specifically, our ability to achieve our anticipated future development and corporate milestones depends on our ability to obtain additional financing on acceptable terms. Forward-looking statements are inherently uncertain and are subject to numerous risks and uncertainties, including: our short operating history and shifts in our business strategy; our operating losses since inception; our need for additional funding to develop our lead drug candidate and our ability to secure additional funding on acceptable terms or at all; the impact of issuances of our common stock, including in the possibility of dilution or a decline in our stock price; our ability to successfully develop our product candidates; unfavorable global economic and financial market conditions; the regulatory environment of our business and our ability to obtain required regulatory approvals; results of non-clinical studies and clinical trials, and risks that non-clinical studies or early clinical trials may not be predictive of results of later-stage clinical trials; delays or difficulties in enrollment of patients in clinical trials; our ability to attract and retain our executives and key employees; legislation of the pharmaceutical and healthcare industries; cybersecurity and data privacy risks; the ability of our products to achieve marketing approval; competition in our industry; our ability to obtain insurance coverage; our dependence on contract research organizations; our ability to protect our intellectual property; public health crises; our ability to maintain proper and effective internal control over financial reporting and other risks disclosed in our Annual Report on Form 10-K for the year ended December 31, 2025, filed with the Securities and Exchange Commission on March 19, 2026. Actual results may differ materially from those indicated by such forward-looking statements as a result of various factors. These risks and uncertainties, as well as other risks and uncertainties that could cause the company’s actual results to differ materially from the forward-looking statements contained herein, are discussed in our Annual 10-K, and other filings with the U.S. Securities and Exchange Commission, which can be found at www.sec.gov. Any forward-looking statements contained in this press release speak only as of the date hereof and not of any future date, and the company expressly disclaims any intent to update any forward-looking statements, whether as a result of new information, future events or otherwise.
Eledon Pharmaceuticals (NASDAQ: ELDN) announced new positive Phase 2 clinical trial results Monday showing that its investigational kidney transplant therapy, tegoprubart, delivered sustained improvements in patient-reported quality of life and transplant-related symptoms compared with tacrolimus, a commonly used immunosuppressive treatment.
The findings, presented at the American Society of Nephrology’s Kidney Week 2026 meeting in Denver, add to previously reported results from Eledon’s Phase 2 BESTOW trial and highlight the potential for a new approach to managing immune suppression following kidney transplantation.
Kidney transplant recipients typically require lifelong immunosuppressive medications to prevent their immune systems from rejecting donated organs. Although existing treatments have significantly improved transplant outcomes, they can produce side effects that affect patients’ daily lives and long-term health.
Eledon’s tegoprubart is designed to address this challenge by targeting CD40 ligand, a protein involved in activating immune responses. Unlike traditional immunosuppressive therapies, the investigational antibody aims to regulate immune activity through a different biological pathway.
The latest BESTOW findings focused on patient-reported outcomes, including physical symptoms, emotional well-being, and overall quality of life during the first year following transplantation.
Researchers evaluated patients using two established assessment tools: the Modified Transplant Symptom Occurrence and Symptom Distress Scale and the Kidney Disease Quality of Life Short Form.
At 12 months, patients receiving tegoprubart demonstrated continued improvements in overall symptom occurrence, while patients treated with tacrolimus experienced a slight worsening compared with their baseline measurements.
Tegoprubart also showed greater symptom improvement in 22 of 23 categories where differences between the treatment groups were observed. These included neurological, gastrointestinal, metabolic, and physical symptoms.
One of the most notable findings involved the Kidney Disease Quality of Life assessment. Patients receiving tegoprubart reported an average nine-point improvement on the Symptoms and Problems Scale, compared with a 3.3-point improvement among patients receiving tacrolimus.
The difference was statistically significant, with Eledon noting that a change of three to five points on the scale can be considered clinically meaningful.
Additional findings suggested potential benefits for mental well-being. Patients treated with tegoprubart experienced a 1.5-point improvement in the mental component summary score, compared with a 1.6-point decline in the tacrolimus group.
The findings suggest that tegoprubart’s potential benefits may extend beyond preventing organ rejection to improving how transplant recipients feel and function in everyday life.
For Eledon, the results provide additional evidence supporting the differentiated clinical profile of its lead drug candidate. Previous BESTOW findings addressed measures of efficacy, kidney function, and safety, while the newly presented data provide further insight into the patient experience.
The development is relevant to investors because kidney transplantation represents a specialized therapeutic market in which effective treatments that reduce medication-related complications could address an important unmet medical need.
However, tegoprubart remains investigational and has not received regulatory approval. Additional clinical development and regulatory review will be necessary before its potential commercial use can be established.
Eledon is also exploring the broader applications of its anti-CD40L technology across other transplantation settings and immune-related conditions, including islet cell transplantation, liver transplantation, and amyotrophic lateral sclerosis.
The latest results underscore growing interest in developing more targeted immunosuppressive treatments that balance the prevention of organ rejection with patients’ long-term quality of life.
For small-cap biotechnology investors, Eledon’s findings represent another clinical development milestone as the company works to advance tegoprubart and demonstrate its potential as an alternative to existing kidney transplant therapies.
Roche is expanding its oncology pipeline through a licensing agreement with Zymeworks (NASDAQ: ZYME) valued at up to $813 million, highlighting continued interest from major pharmaceutical companies in experimental cancer treatments developed by smaller biotechnology firms.
The agreement, announced October 23, 2026, gives Swiss pharmaceutical giant Roche exclusive worldwide rights to develop and commercialize ZW209, an investigational therapy designed to treat certain cancers, including small-cell lung cancer.
Under the agreement, Zymeworks will receive an upfront payment of $55 million, followed by an additional $40 million if Roche initiates a planned Phase 1b clinical trial. The biotechnology company could also receive up to $718 million in development, commercial, and sales-related milestone payments, along with royalties on future sales of approved treatments.
The full $813 million value is contingent on achieving specified milestones and does not represent guaranteed revenue.
ZW209 belongs to an emerging class of cancer therapies known as trispecific T-cell engagers. These treatments are designed to help the immune system recognize and attack cancer cells by connecting immune cells with specific targets found on tumors.
The experimental drug targets DLL3, a protein frequently expressed in small-cell lung cancer and certain other neuroendocrine tumors but generally found at low levels in healthy tissue.
ZW209 is designed to engage DLL3 while simultaneously interacting with two proteins on immune cells, CD3 and CD28. This approach aims to stimulate an immune response against cancer cells while potentially improving the effectiveness and durability of treatment.
The drug remains in early clinical development, and its safety and effectiveness in patients have not yet been established.
Zymeworks will conduct the Phase 1a portion of the clinical program in collaboration with Roche, which will fund the study. Roche will subsequently assume responsibility for global development and commercialization.
The first patient is expected to enter the study before the end of 2026, according to Zymeworks management.
For investors, the transaction illustrates an important strategy in the biotechnology industry: smaller drug developers can use licensing agreements to secure funding and share clinical development risks while retaining opportunities for future milestone payments and royalties.
These partnerships can be particularly valuable for emerging biotechnology companies, where clinical trials require substantial investment and successful commercialization often depends on extensive manufacturing, regulatory, and distribution capabilities.
Roche’s decision to partner on ZW209 before human efficacy data are available also underscores the importance pharmaceutical companies place on differentiated scientific platforms and promising early-stage research.
The agreement reflects broader interest in innovative oncology treatments, including immunotherapies and therapies designed to target specific biological mechanisms involved in cancer.
Within Noble Capital Markets’ research coverage universe, Greenwich LifeSciences (NASDAQ: GLSI) is developing an investigational immunotherapy for breast cancer, while Cardiff Oncology (NASDAQ: CRDF) is advancing onvansertib, an experimental cancer treatment targeting the PLK1 enzyme. Although their technologies differ from ZW209, these companies illustrate the range of oncology approaches being pursued by emerging biotechnology developers. Neither company is involved in the Roche-Zymeworks agreement.
The transaction also highlights the potential financial importance of early-stage biotechnology partnerships. Rather than acquiring entire companies, larger pharmaceutical businesses can license individual drug candidates, gaining access to promising technologies while limiting their initial financial commitments.
However, significant risks remain. Experimental cancer treatments face lengthy clinical trials, regulatory scrutiny, and uncertainty surrounding patient outcomes. Milestone payments depend on future progress, and many investigational therapies never reach commercialization.
The Roche-Zymeworks agreement remains subject to customary closing conditions, including applicable antitrust clearance.
For small-cap biotechnology investors, the deal provides another example of how innovative drug-development platforms can attract major pharmaceutical partners. As competition for differentiated cancer treatments continues, licensing agreements may remain an important source of funding and strategic validation for emerging biotech companies.
Lycia Therapeutics is preparing to raise approximately $250 million through an initial public offering, becoming the latest biotechnology company seeking to capitalize on renewed investor interest in emerging drug developers. The South San Francisco-based company announced plans Tuesday to offer 14.7 million shares priced between $16 and $18 each, potentially valuing the business at approximately $950 million on a fully diluted basis.
The company intends to list on the Nasdaq under the ticker symbol LYCA, adding another early-stage biotechnology developer to a growing pipeline of healthcare IPOs. The offering comes as investors increasingly look beyond established pharmaceutical companies toward emerging businesses developing innovative treatments for diseases with significant unmet medical needs.
Lycia is developing a new class of medicines designed to eliminate disease-causing proteins from the body. Its proprietary LYTAC technology, short for Lysosomal Targeting Chimera, works by directing specific proteins toward the body’s natural cellular disposal system. Unlike traditional drugs that primarily block the activity of harmful proteins, Lycia’s approach aims to remove them altogether.
The technology is based on research associated with Nobel Prize-winning chemist Carolyn Bertozzi, who helped establish the company in 2019. Lycia is initially targeting autoimmune, inflammatory, and allergic diseases, areas where conventional treatments often require ongoing symptom management.
Its lead experimental treatment, LCA-0061, is being developed for food allergies and other allergic conditions. The therapy targets immunoglobulin E, or IgE, an antibody responsible for triggering many allergic reactions. Early Phase 1 results showed a mean maximum IgE reduction of 96% from baseline among treated participants in an initial small cohort, although larger studies will be needed to determine its safety and effectiveness in patients.
Lycia is also developing LCA-0321, an experimental treatment for Graves’ disease, an autoimmune condition affecting the thyroid. The candidate is designed to selectively eliminate disease-causing antibodies rather than broadly suppress the immune system.
Lycia’s focus on targeted therapies for autoimmune and inflammatory conditions also reflects broader innovation across the biotechnology sector. Eledon Pharmaceuticals (NASDAQ: ELDN) is developing tegoprubart, an investigational treatment designed to regulate immune system activity by targeting the CD40 ligand pathway, with applications in organ transplantation. Meanwhile, Gyre Therapeutics (NASDAQ: GYRE) is focused on developing treatments for inflammatory and fibrotic diseases, including liver-related conditions. Although these companies employ different scientific approaches, their development programs highlight growing interest in therapies that address specific biological mechanisms underlying complex diseases.
Proceeds from the IPO are expected to support clinical development of these programs, additional research activities, and general corporate operations. The company has already raised approximately $267 million from private investors, including several prominent life sciences investment firms.
The planned offering follows a series of biotechnology IPOs that suggest improving conditions for companies seeking public-market financing. City Therapeutics and Iambic Therapeutics recently completed offerings that raised approximately $350 million combined, highlighting investor interest in RNA-based medicines and artificial intelligence-driven drug discovery.
While these companies are pursuing different technologies, their emergence reflects a broader shift toward specialized drug development platforms that could generate multiple treatments across different diseases.
For investors, Lycia’s proposed IPO offers exposure to an emerging area of biotechnology known as targeted protein degradation. The technology could eventually expand treatment possibilities for diseases where existing therapies have limited effectiveness, although its clinical and commercial potential remains unproven.
The offering also carries substantial risks. Lycia remains an early-stage clinical developer without an approved commercial product, and its future valuation will depend heavily on clinical trial results, regulatory progress, and its ability to finance continued research.
As more biotechnology companies test public-market demand, Lycia’s offering could provide another indication of whether investor appetite for early-stage drug developers is strengthening heading into the final months of 2026.
CAMBRIDGE, Mass., Oct. 19, 2026 /PRNewswire/ — NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) (“NeuroSense” or the “Company”), a late-stage clinical biotechnology company developing treatments for neurodegenerative diseases, today announced that it has filed a patent application with the U.S. Patent and Trademark Office covering methods of treating traumatic brain injury (TBI) and related central nervous system injuries with the combination of ciprofloxacin and celecoxib, the active ingredients of PrimeC.
The application covers the treatment of a broad range of brain injuries, from concussion and mild TBI to moderate and severe TBI, including blast-related injury, as well as their long-term consequences, such as chronic traumatic encephalopathy (CTE). If granted, the patent is expected to provide protection through 2047, subject to any extensions.
Traumatic brain injury (TBI) represents a major global healthcare challenge, affecting millions of people each year. TBI can result from falls, motor vehicle accidents, sports-related injuries and military-related trauma, including blast exposure. Its consequences can extend well beyond the initial event, potentially causing persistent cognitive, physical and behavioral impairment, with substantial burdens on patients, caregivers and healthcare systems. Despite this significant unmet medical need, there are currently no approved disease-modifying therapies specifically targeting the secondary neurological injury associated with TBI.
Following the initial trauma, TBI can trigger complex biological processes, including neuroinflammation, oxidative stress and progressive neuronal damage. Certain mechanisms overlap with pathways implicated in neurodegenerative disorders.
The patent filing also supports NeuroSense’s longer-term strategy of pursuing additional applications for PrimeC beyond its existing development programs. The Company views TBI as an opportunity to broaden PrimeC’s commercial potential and build additional long-term value around its lead asset. While ALS remains NeuroSense’s primary development priority, the Company is evaluating future TBI-focused research and development initiatives, through strategic collaborations, research grants and other non-dilutive funding opportunities.
“While ALS remains our primary focus, we believe PrimeC may have potential across a broader range of neurological conditions that share common underlying disease mechanisms,” said Alon Ben-Noon, Chief Executive Officer of NeuroSense. “TBI is a particularly compelling area given the large affected population, the long-term consequences of brain injury and the lack of approved disease-modifying treatments. This filing strengthens our intellectual property position and creates a foundation for future research, partnerships and non-dilutive funding opportunities, while maintaining our focus on advancing our core ALS program. We look forward to sharing further updates as our clinical and strategic initiatives advance.”
About NeuroSense
NeuroSense Therapeutics is a late-clinical stage biotechnology company developing novel treatments for severe neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and Alzheimer’s disease. The Company’s lead product candidate, PrimeC, is a novel oral therapy designed to target multiple key biological pathways underlying disease progression, including neuroinflammation, oxidative stress and dysregulated iron metabolism.
NeuroSense has recently completed analysis of long-term follow-up data from its Phase 2b PARADIGM study in ALS, with results published in JAMA Neurology showing slower functional decline in participants who received PrimeC from study start than in those who initially received placebo. The Company also reported changes across multiple biomarkers associated with ALS, including microRNAs, consistent with PrimeC’s multi-target mechanism of action.
NeuroSense has received clearance from the U.S. Food and Drug Administration (FDA) to initiate its pivotal Phase 3 clinical trial (PARAGON) in ALS, to be conducted primarily in the United States. The Company is working with FDA on an optimized design for the study.
For additional information, we invite you to visit our website and follow us on LinkedIn, YouTube and X. Information that may be important to investors may be routinely posted on our website and these social media channels.
About PrimeC
PrimeC, NeuroSense’s lead drug candidate, is a novel extended-release oral formulation composed of a unique fixed-dose combination of two FDA-approved drugs: ciprofloxacin and celecoxib. PrimeC is designed to target several key mechanisms that contribute to neuron degeneration, inflammation, iron accumulation and impaired ribonucleic acid (“RNA”) regulation, with the potential to inhibit disease progression.
About ALS
Amyotrophic lateral sclerosis (“ALS”) is an incurable neurodegenerative disease that causes progressive paralysis and, typically, death within 3 years of symptoms onset. Every year, more than 5,000 people are diagnosed with ALS in the U.S. alone, with an annual disease burden of $1 billion. The number of people living with ALS is expected to grow by 24% by 2040 in the U.S. and EU.
Forward-Looking Statements
This press release contains “forward-looking statements” that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as “anticipate,” “believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,” “seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “target,” “aim,” “should,” “will,” “would,” or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on NeuroSense Therapeutics’ current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict and include statements regarding the Company’s development program, including for ALS and TBI, the potential issuance, scope and duration of patent protection arising from the Company’s patent application, including expected protection through 2047, subject to any extensions, the potential of PrimeC to treat TBI and related central nervous system injuries, the potential expansion of PrimeC beyond ALS and its potential commercial benefits and long-term value. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. The future events and trends may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements. These risks include the risk that the patent application will not result in an issued patent or that any patent granted will not provide the Company with the anticipated scope or duration of protection or will be challenged, invalidated or unenforceable; the risk that PrimeC will not demonstrate safety or efficacy in TBI or related conditions; the potential for delay in the timing of the Phase 3 clinical trial (PARAGON) in ALS; the risk that the Company will not be able to obtain financing on acceptable terms, or at all; the risk that the Company will not regain and maintain compliance with the Nasdaq listing requirements; the risk that non-dilutive grant funding for the PARAGON trial will not be awarded or will be delayed; uncertainty regarding outcomes and the timing of current and future clinical trials; the risk that PrimeC will not advance towards later-stage development; timing for reporting data, including from the study of PrimeC in Alzheimer’s disease; that the study will not be successful; and other risks and uncertainties set forth in NeuroSense’s filings with the Securities and Exchange Commission (SEC). You should not rely on these statements as representing our views in the future. More information about the risks and uncertainties affecting NeuroSense is contained under the heading “Risk Factors” in the Annual Report on Form 20-F filed with the Securities and Exchange Commission on March 31, 2026 and NeuroSense’s subsequent filings with the SEC. Forward-looking statements contained in this announcement are made as of this date, and NeuroSense undertakes no duty to update such information except as required under applicable law.
SOURCE NeuroSense
For further information: For further information: Email: [email protected] | Tel: +972-(0)9-799-6183
Robert LeBoyer, Senior Vice President, Equity Research Analyst, Biotechnology, Noble Capital Markets, Inc.
Refer to the full report for the price target, fundamental analysis, and rating.
Patient Enrollment and Treatment Continue. Nanoviricides provided an update on the progress of its Phase 2a trial in Ebola, including additional details on its design, endpoints, and objectives. The Phase 2a trial began treating patients with NV-387 in the Democratic Republic of Congo (DRC) in late September. The company reported that enrollment is continuing, with data expected in 1Q27.
Stages Of Infection Are Emerging. The current outbreak of Ebola virus disease (EVD) in the DRC has been caused by a new variant of the Bundibugyo Ebolavirus (BDBV). The development of symptoms varies between patients, and its diagnosis is still being refined. During the first 5 to 7 days after initial infection, mild symptoms may not even be noticeable. Patients typically seek treatment after about 5 to 7 days, when they begin vomiting and have severe diarrhea. The trial is expected to enroll most patients at this stage.
Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.
This Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).
*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision.
MALVERN, Pa., Oct. 14, 2026 (GLOBE NEWSWIRE) — Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced the execution of a licensing agreement with Roots Pharmaceutical, and its strategic partner Al-Dhow International Holding, for the exclusive rights to OCU400, Ocugen’s novel modifier gene therapy for the treatment of Retinitis Pigmentosa (RP), in the Middle East and North Africa (MENA) region.
Subject to the terms of the License Agreement, Ocugen will receive an upfront license fee and potential initial development milestone payments of up to $4 million, in the aggregate, as well as potential sales milestone payments of up to $255 million, and royalties equaling 22% of OCU400 net sales generated by Roots Pharmaceutical. Ocugen will manufacture the commercial supply of OCU400 under terms of a related supply agreement.
Ocugen believes RP is a leading cause of inherited vision loss globally, with a particularly significant unmet need across the MENA region, where the prevalence of RP is estimated to be 10 to 20 times higher than in the U.S. and EU. Through OCU400, Roots Pharmaceutical aims to help address this substantial unmet need by potentially providing a treatment option for people in the MENA region living with RP and facing progressive vision loss and potential blindness.
“By partnering with Roots Pharmaceutical, an established leader with strong reach across the Middle East and North Africa, we are expanding our ability to bring our potential one-time gene therapy to patients in a region where retinitis pigmentosa is highly prevalent and the unmet medical need is significant,” said Dr. Shankar Musunuri, Chairman, Chief Executive Officer and Co-founder of Ocugen. “This agreement represents another important step in our strategy to build strong regional partnerships and expand global access to our potentially transformational gene therapies.”
Roots Pharmaceutical is an established and rapidly growing pharmaceutical company serving key markets across the MENA region. With more than two decades of operating experience and expertise in commercializing innovative medicines, the company’s regional capabilities and established healthcare relationships position it as a strong partner for bringing OCU400 to RP patients across MENA.
“This partnership reflects Roots’ commitment to bringing breakthrough gene therapies to the Middle East and North Africa, leading and shaping the treatment paradigm for our patients, which is our main objective,” said Dr. Islam Zayed, Chief Executive Officer and Co-Founder of Roots Pharmaceutical. “OCU400 has the potential to change the outlook, and the lives, of patients living with retinitis pigmentosa. We look forward to working closely with Ocugen to build the diagnosis-to-treatment pathway that gene therapy requires across our markets, and to exploring further collaboration across Ocugen’s ophthalmology pipeline.”
Ocugen continues to advance OCU400 through its Phase 3 liMeliGhT clinical trial with a topline data readout expected in the first quarter of 2027, followed by global regulatory submissions, including a Biologics License Application in the U.S. and a Marketing Authorization Application in Europe.
About Ocugen, Inc. Ocugen, Inc. is a pioneering biotechnology company developing gene therapies for blindness diseases. The Company’s breakthrough modifier gene therapy platform has the potential to address significant unmet medical needs across large patient populations through a gene-agnostic approach. Unlike traditional gene therapies and gene-editing technologies that target a single gene mutation, Ocugen’s modifier gene therapies are designed to address the underlying disease biology by restoring balance across multiple gene networks. The Company is currently advancing programs for inherited retinal diseases and other causes of blindness that affect millions worldwide, including retinitis pigmentosa, Stargardt disease, and geographic atrophy, an advanced form of dry age-related macular degeneration. Discover more at www.ocugen.com and follow the Company on LinkedIn and X.
About Roots Pharmaceutical Company Founded in Kuwait in 2006, Roots Pharmaceutical is a fully integrated healthcare provider specializing in commercializing innovative therapies, medical devices, and an aesthetic line across the Middle East and North Africa. It is led by a team with over 25 years of pharmaceutical industry experience.
Roots Pharmaceuticals has established a direct commercial presence in the MENA region (Middle East and North Africa), mainly in GCC countries and key North African countries, with a therapeutic portfolio spanning neurology, hematology, oncology, rare diseases, dermatology, cardiovascular, medical devices and aesthetic line.
With 30+ global partners and a $300M+ product pipeline, Roots Pharmaceutical and its strategic partner Al-Dhow Group are committed to delivering meaningful healthcare impact across the MENA region through innovation, access and excellence. Its operations are ISO 9001:2015-certified and externally audited by PwC.
Cautionary Note on Forward-Looking Statements This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding the anticipated benefits to Ocugen of the definitive license agreement and supply agreement with Roots Pharmaceutical Company, as well as statements regarding strategy, the potential amounts of milestone payments and royalty payments that may be received under the license agreement, business plans and objectives for Ocugen’s clinical programs, plans and timelines for the preclinical and clinical development of Ocugen’s product candidates, including the therapeutic potential, clinical benefits and safety thereof, expectations regarding timing, success and data announcements of current ongoing preclinical and clinical trials, including the timing of data readouts and marketing applications, the ability to initiate new clinical programs, statements regarding qualitative assessments of available data, potential benefits, expectations for ongoing clinical trials, anticipated regulatory filings and anticipated development timelines, statements regarding potential market size and commercial possibilities of Ocugen’s product candidates, which are subject to risks and uncertainties. Ocugen may, in some cases, use terms such as “predicts,” “believes,” “potential,” “proposed,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should,” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Such statements are subject to numerous important factors, risks, and uncertainties that may cause actual events or results to differ materially from Ocugen’s current expectations, including, but not limited to, the risks that the license agreement and supply agreement with Roots Pharmaceutical Company will not lead to the current anticipated benefits to Ocugen; that preliminary, interim and top-line clinical trial results may not be indicative of, and may differ from, final clinical data; that unfavorable new clinical trial data may emerge in ongoing clinical trials or through further analyses of existing clinical trial data; that earlier non-clinical and clinical data and testing may not be predictive of the results or success of later clinical trials; and that clinical trial data are subject to differing interpretations and assessments, including by regulatory authorities. These and other risks and uncertainties are more fully described in Ocugen’s filings with the Securities and Exchange Commission (SEC), including the risk factors described in the section entitled “Risk Factors” in the quarterly and annual reports that Ocugen files with the SEC. Any forward-looking statements that Ocugen makes in this press release speak only as of the date of this press release. Except as required by law, Ocugen assumes no obligation to update forward-looking statements contained in this press release whether as a result of new information, future events, or otherwise, after the date of this press release.
Major pharmaceutical companies are approaching a significant patent cliff that could accelerate mergers and acquisitions across the biotechnology sector. With an estimated $300 billion to $400 billion in pharmaceutical revenue facing patent-related pressure beginning in 2028, large drugmakers are looking for ways to replenish their pipelines and offset potential losses from expiring blockbuster drug patents.
For small-cap biotechnology companies, this shift could create new opportunities through acquisitions, licensing agreements, and strategic partnerships. Companies developing innovative treatments in oncology, gene therapy, and immunology may benefit from increased industry interest as major pharmaceutical manufacturers search for their next generation of revenue-producing therapies.
What Is the Big Pharma Patent Cliff?
The pharmaceutical patent cliff refers to the expiration of patent protection or market exclusivity on major branded medications. Once these protections expire, generic drugs and biosimilars can enter the market, potentially reducing sales of previously protected products.
For pharmaceutical companies that rely heavily on blockbuster medications, the resulting revenue pressure can be substantial. Replacing that revenue often requires years of research, clinical development, and regulatory approvals.
As a result, major drugmakers may increasingly look beyond their internal research programs to acquire or partner with smaller biotechnology companies developing promising treatments.
Why Patent Expirations Could Drive Biotech Mergers and Acquisitions
Acquiring smaller biotechnology companies can provide large pharmaceutical manufacturers with access to innovative drug candidates, specialized technologies, and established clinical development programs.
Rather than developing every new treatment internally, pharmaceutical companies can pursue acquisitions, licensing agreements, or strategic partnerships to expand their pipelines.
Oncology, immunology, rare diseases, and other specialized therapeutic areas remain important areas of strategic interest.
For small-cap biotech companies, these relationships can provide access to capital and development resources. However, the potential for acquisition interest depends on factors such as clinical results, intellectual property protection, regulatory progress, and the strategic priorities of prospective partners.
Small-Cap Biotech Companies Advancing New Treatments
Several emerging biotechnology companies are developing treatments in therapeutic areas relevant to the pharmaceutical industry’s long-term growth strategies.
Cardiff Oncology (CRDF): Advancing Onvansertib for Colorectal Cancer
Cardiff Oncology (NASDAQ: CRDF) is developing onvansertib, a PLK1 inhibitor being studied in combination with standard therapies for metastatic colorectal cancer.
The company has reported encouraging Phase 2 clinical results and outlined plans for a registrational trial, subject to additional financing.
Cardiff Oncology’s development program illustrates the type of clinical-stage innovation occurring within the small-cap biotechnology sector, particularly in oncology, where companies continue to investigate new approaches to treating difficult cancers.
Ocugen (OCGN): Gene Therapy and Strategic Licensing Opportunities
The company has pursued regional licensing opportunities as part of its broader development strategy, demonstrating how smaller biotechnology firms can seek additional resources while retaining certain commercial rights.
Licensing agreements can provide an alternative to outright acquisitions, allowing pharmaceutical partners to access emerging technologies without assuming the full cost of developing or purchasing a company.
Eledon Pharmaceuticals (ELDN): Immunology and Kidney Transplant Research
Eledon Pharmaceuticals (NASDAQ: ELDN) is advancing treatments involving immune modulation, including tegoprubart, an investigational therapy being studied in kidney transplantation.
Its development program reflects ongoing innovation in immunology and transplantation, therapeutic areas where unmet medical needs continue to drive research.
Cardiff Oncology, Ocugen, and Eledon represent different approaches to drug development. Their inclusion illustrates the diversity of clinical-stage innovation within the small-cap biotechnology sector and does not imply that acquisition discussions involving these companies are underway.
What Should Small-Cap Biotech Investors Watch?
Although the pharmaceutical patent cliff may encourage additional dealmaking, acquisition potential alone should not determine how investors evaluate biotechnology companies.
Clinical progress remains a critical consideration, particularly for companies that have not yet generated meaningful commercial revenue.
Investors following the sector should pay attention to several developments:
Clinical trial results: Positive data can strengthen a company’s development outlook, while disappointing results can create significant setbacks.
Regulatory milestones: Progress toward pivotal trials and potential approvals can influence a company’s prospects.
Cash reserves and financing: Many clinical-stage biotechnology companies depend on external capital to fund research and development.
Intellectual property: Patent protection and other exclusivity rights can influence the commercial value of emerging therapies.
Licensing and partnership announcements: Strategic agreements may provide financing, development support, or commercial opportunities.
Investors should also distinguish between acquisitions and licensing arrangements. Pharmaceutical companies may choose partnerships that provide access to promising treatments without taking on the full financial and operational responsibilities of an acquisition.
Could the Patent Cliff Accelerate Biotech M&A Activity?
Following a slowdown in biotechnology dealmaking over the summer, industry observers anticipate renewed acquisition interest as pharmaceutical companies prepare for upcoming patent expirations.
For the small-cap biotechnology sector, increased dealmaking could have implications beyond individual takeover transactions.
Strategic acquisitions and partnerships may establish valuation benchmarks for emerging therapeutic platforms, create financing opportunities, and influence investor sentiment across the industry.
However, these potential benefits remain dependent on clinical success, market conditions, and the willingness of larger pharmaceutical companies to pursue transactions.
As major drugmakers prepare for substantial patent-related revenue pressure, smaller biotechnology companies developing innovative treatments could play an increasingly important role in the industry’s long-term growth strategy.
Viatris (Nasdaq: VTRS) announced Thursday it has agreed to acquire Pacira BioSciences (Nasdaq: PCRX) for $36.50 per share in cash, an aggregate equity value of $1.65 billion. The deal gives Viatris two marketed, patent-protected non-opioid pain medicines and positions the company as a leader in a category where patients and physicians continue to look for alternatives to opioids.
Pacira’s portfolio rests on EXPAREL, a long-acting local anesthetic used to manage pain after surgery, and ZILRETTA, an extended-release injection for osteoarthritis knee pain. Company materials cite up to a 78% decrease in opioid consumption with EXPAREL, though the release notes the clinical benefit of that reduction was not demonstrated. Over the twelve months ended June 30, 2026, Pacira generated about $746 million in revenue and $177 million in adjusted EBITDA. On equity value alone, the price works out to roughly 2.2 times revenue and 9.3 times adjusted EBITDA. GAAP net income over the same period was a much smaller $14.6 million, reflecting significant amortization of acquired intangibles and stock-based compensation.
Viatris says the acquisition advances its push to build an innovative medicines business, and that the products complement its fast-acting meloxicam opportunity in pain. The company also gains Pacira’s U.S. commercial, market access, medical affairs, and research capabilities, along with a pipeline led by a Phase 2 gene therapy candidate for knee osteoarthritis. Viatris plans to apply its expertise in intellectual property and product lifecycle management to extend the portfolio’s reach, including across select international markets where it already operates.
Viatris expects to fund the deal primarily from excess cash, with the remainder from short-term borrowings, and says the impact on its gross leverage ratio will be minimal. The transaction is expected to be immediately accretive to its financial guidance metrics. It will be structured as a tender offer followed by a second-step merger at the same price, with both boards having unanimously approved and Pacira’s board recommending that shareholders tender. Closing requires that a majority of Pacira’s outstanding shares be tendered and that the regulatory waiting period expire, and is expected by the end of 2026. Once complete, Pacira will be delisted from Nasdaq. Viatris will discuss the transaction when it reports third-quarter results on November 5.
Pacira’s leadership said the company has helped nearly 20 million patients access non-opioid pain management and that Viatris’ scale and resources will help bring its therapies to more patients.
The thesis behind the deal is worth examining. Viatris highlighted its record of sustaining sales after competition arrives, a reminder that protected products do not stay protected forever and that part of what Viatris is paying for is its ability to manage that transition.
For small and microcap investors, the takeaway is that commercial-stage healthcare companies with profitable, differentiated products are drawing strategic interest at disciplined valuations. Roughly nine times adjusted EBITDA on equity value is a useful benchmark for smaller specialty pharma and medical technology companies with established revenue, and it reinforces a theme running through this year’s healthcare deal activity, including Supernus’s merger with Indivior and MiMedx’s acquisition of Sanara MedTech. Companies still in development are a different proposition, since their deal values depend far more on clinical milestones than on current earnings.
Robert LeBoyer, Senior Vice President, Equity Research Analyst, Biotechnology, Noble Capital Markets, Inc.
Refer to the full report for the price target, fundamental analysis, and rating.
MAIA Reported Two Important Clinical Trial Milestones. MAIA announced the completion of enrollment for the Part C Expansion Stage of the THIO-101 trial. This part of THIO-101 has enrolled 150 patients. Separately, the Phase 3 THIO-104 trial reached enrollment of 65 patients, putting it on schedule to enroll 100 patients by YE2026. Reaching the full-year enrollment goal could allow an interim analysis in FY2027.
Results From THIO-101 Part C Have Been Positive To Date. As discussed in our Research Note on September 22, MAIA recently announced initial efficacy data from the THIO-101 Part C. The evaluable population, consisting of patients with at least one post-treatment evaluation by tumor scan, showed a disease control rate (DCR) of 90.5%. This far exceeds published studies that show a 25%–35% DCR for standard third-line chemotherapy regimens.
Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.
This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).
*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision.
Gate Bioscience, a privately held drug discovery company, announced Monday that it has expanded its research and licensing agreement with Eli Lilly (NYSE: LLY) in a deal now potentially worth more than $870 million. The original agreement, announced in July 2025, was worth up to $856 million. The expansion adds one drug target, with an option to add a second.
Gate will receive an upfront payment and research funding for the added target, plus an additional payment if the second target is selected. Neither company disclosed the size of the upfront payment. Gate is also eligible for milestone payments and royalties on global sales of any products that result.
The science behind the partnership takes a different approach to disease. Gate uses its platform to discover oral small-molecule drugs designed to eliminate proteins that have been difficult to target with existing medicines. Many conventional drugs work by blocking a protein’s activity, but some disease-driving proteins offer no good place for a drug to bind. A drug built to remove the protein altogether can reach targets once considered out of reach.
The two companies have split the work along familiar lines. Gate leads discovery, while Lilly takes over late-stage preclinical and clinical development, manufacturing, and commercialization. Lilly holds exclusive worldwide rights to products developed against the selected targets.
The deal fits a pattern in Lilly’s strategy this year. The company has acquired Merida Biosciences, which is developing biologics that eliminate disease-causing autoantibodies, and AtaiBeckley, a clinical-stage mental health company, while also signing earlier-stage platform partnerships like this one. Buying finished assets and renting promising discovery engines are two ways of filling the same pipeline.
The headline number deserves context. The expansion lifts the potential value by only about $14 million over the original agreement, which shows how these figures work. Partnership values are usually quoted at their maximum, with most of the money tied to development and sales milestones that may never be paid. The undisclosed upfront payment is the figure that actually reaches the company’s balance sheet.
The same partnership playbook is open to smaller companies pursuing oral small-molecule medicines. Cocrystal Pharma, which uses a structure-based discovery platform to develop antiviral drugs, and Cardiff Oncology, whose lead candidate onvansertib is an oral small molecule being studied in colorectal cancer, work in different therapeutic areas than Gate, and neither focuses on protein elimination. But both illustrate the model investors are watching: a differentiated discovery approach or oral drug candidate that could eventually attract a larger development partner.
For investors tracking small and microcap biotech, the takeaway cuts both ways. Large pharma remains willing to sign collaborations worth hundreds of millions of dollars with private platform companies before any drug reaches the clinic, a sign of continued appetite for differentiated discovery technology. But a platform deal is not an approved product. The upfront cash, the pace of milestone payments, and whether the partner keeps selecting targets matter most, and investors weighing smaller developers with similar partnership ambitions should read the fine print on all three.
